Table 2 Summary of febrile neutropenia incidence based on meta-analyses of trials of G-CSFs
Treatment 1 | Treatment 2 | No of studies | No of patients | Relative risk of FN (95% CI) | p-value | I2 (heterogeneity) |
|---|---|---|---|---|---|---|
Pegfilgrastim | No primary G-CSF | 5 | 2060 | 0.30 (0.14 to 0.65) | p = 0.002 | 76% |
Filgrastim | No primary G-CSF | 10 | 2183 | 0.57 (0.48 to 0.69) | p < 0.00001 | 50% |
Lenograstim | No primary G-CSF | 5 | 467 | 0.62 (0.44 to 0.88) | p = 0.007 | 64% |
Any G-CSF | No primary G-CSF | 20 | 4710 | 0.51 (0.41 to 0.62) | p < 0.00001 | 74% |
Pegfilgrastim | Filgrastim | 5 | 606 | 0.66 (0.44 to 0.98) | p = 0.04 | 0% |